<DOC>
	<DOC>NCT00941746</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).</brief_summary>
	<brief_title>Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Moderate to severe pain attributed to knee osteoarthritis Significant comorbidity Significant pain states other than osteoarthritis Concomitant medications that might affect assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>